Using DNA to reveal the drivers of disease
Sponsored by IMO Health
We’re getting a clearer picture than ever before about how our genomes influence disease.
Researchers have finally mapped the once-unmappable regions of the human genome to release the first fully completed version of a human genome. Researchers are working with families with rare conditions caused by genetic mutations to glean new insights into what drives disease, and what protects against it.
At the same time, there has been significant progress in using DNA to not just understand disease, but also figure out the best way to treat it. Biotech and pharma companies are scrutinizing genetic mutations to find the most promising targets for new drug candidates. And clinicians are now regularly using DNA to more precisely tailor cancer treatments to a particular patient.
What impact have these advances had? And what direction is the field headed next? These stories offer a look at what we’ve learned about the genome’s role in disease and drug development, and what’s still to come.
Enter the information below to begin your free e-book download
About the sponsor
About the sponsor
Intelligent Medical Objects is a healthcare data enablement company that ensures clinical data integrity and quality—making patient information fit-for-purpose across the healthcare ecosystem, from hospitals to health information exchanges to payers, and beyond.
IMO’s vast footprint in EHRs powers our ability to capture and preserve clinical intent at the highest level of specificity. Our secure technology platform and products then help our clients to transform and extract the greatest value from their data.
In short, IMO is the catalyst that enables accurate documentation, precise population cohorting, optimized reimbursements, robust analytics, and better care decisions to optimize patient outcomes.